Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 13, 2022 (4 years ago)

Metronidazole tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations: Temperature abuse

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Metronidazole tablets, USP 250 mg, 100-count unit dose box, Rx only, MFG: Major Pharma, NDC 0904-1453-61

Affected NDC 0904-1453-61

Compare with the code on your package — it is the most precise check available.

Drug: Metronidazole Category: Antibiotic

Recalling firm
Mckesson Medical-Surgical Inc. Corporate Office
NDC code
0904-1453-61
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1056-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metronidazole recalls

See all
Class II · Moderate risk

Metronidazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-001-24 D-0616-2017

Other recalls by Mckesson Medical-Surgical Inc. Corporate Office

All 2022 recalls
Class II · Moderate risk

Infuvite Adult

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 54643-5649-1 D-0401-2025
Class II · Moderate risk

Medroxyprogesterone Acetate Injectable Suspension

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-0330-01 D-0400-2025
Class II · Moderate risk

BENLYSTA (belimumab)

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 49401-102-01 D-0540-2025
Class II · Moderate risk

Evenity

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55513-880-02 D-0539-2025